Literature DB >> 7578423

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

R J Griffin1, N J Curtin, D R Newell, B T Golding, B W Durkacz, A H Calvert.   

Abstract

Poly(ADP-ribose) polymerase (PARP) plays an important role in a number of cellular processes including DNA repair. Since poly(ADP-ribosyl)ation occurs in response to radiation- or drug-induced DNA damage, inhibitors of the enzyme may enhance the antitumour activity of radiotherapy or cytotoxic drug treatment. In this review the development of PARP inhibitors is discussed, and structure-activity relationships amongst inhibitors of the enzyme are presented. Studies to date regarding the in vitro and in vivo activity of PARP inhibitors, as resistance modifying agents in cancer therapy, are also overviewed.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7578423     DOI： 10.1016/0300-9084(96)88154-5

Source DB:  PubMed          Journal:  Biochimie        ISSN： 0300-9084            Impact factor:   4.079


  13 in total

1.  Molecular cloning of an apoptosis-inducing protein, pierisin, from cabbage butterfly: possible involvement of ADP-ribosylation in its activity.

Authors:  M Watanabe; T Kono; Y Matsushima-Hibiya; T Kanazawa; N Nishisaka; T Kishimoto; K Koyama; T Sugimura; K Wakabayashi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

3.  Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken.

Authors:  A Ruf; J Mennissier de Murcia; G de Murcia; G E Schulz
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 4.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

5.  Identification of three critical acidic residues of poly(ADP-ribose) glycohydrolase involved in catalysis: determining the PARG catalytic domain.

Authors:  Chandra N Patel; David W Koh; Myron K Jacobson; Marcos A Oliveira
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

6.  Poly(ADP-ribose) polymerase enhances activator-dependent transcription in vitro.

Authors:  M Meisterernst; G Stelzer; R G Roeder
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

7.  Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.

Authors:  Debashree Basudhar; Robert C Cheng; Gaurav Bharadwaj; Lisa A Ridnour; David A Wink; Katrina M Miranda
Journal:  Free Radic Biol Med       Date:  2015-02-04       Impact factor: 7.376

8.  Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2.

Authors:  Antony W Oliver; Jean-Christophe Amé; S Mark Roe; Valerie Good; Gilbert de Murcia; Laurence H Pearl
Journal:  Nucleic Acids Res       Date:  2004-01-22       Impact factor: 16.971

9.  Drug resistance and DNA repair in leukaemia.

Authors:  M R Müller; J Thomale; M F Rajewsky; S Seeber
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

10.  Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.

Authors:  Francesco Sabbatino; Celeste Fusciello; Domenico Somma; Roberto Pacelli; Ravin Poudel; David Pepin; Antonio Leonardi; Chiara Carlomagno; Giuseppina Della Vittoria Scarpati; Soldano Ferrone; Stefano Pepe
Journal:  Cytometry A       Date:  2014-09-02       Impact factor: 4.355
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.